Loading...
New

Asia-Pacific Oncology Molecular Diagnostics Market by Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Hematological Cancer & Others), End User (Hospitals, Reference Laboratories, & Others), Country (Australia, Vietnam, Thailand, Philippines & Rest of Asia-Pacific): Regional Opportunity Analysis and Industry Forecast, 2019–2026

A06287
Pages: 158
May 2020 | 1241 Views
 
Author(s) : Komal Urde & Onkar Sumant
Tables: 87
Charts: 39
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Asia-pacific Oncology Molecular Diagnostics Market

Request Now !

The Asia-Pacific oncology molecular diagnostics market was valued at $381.84 million in 2018 and is estimated to reach $732 million by 2026 growing at a CAGR of 9% for the forecast period of 2019–2026.

Molecular diagnosis is a method used to identify a disease at the molecular level, such as proteins, DNA, and RNA, in a tissue or fluid. Various tools are used to detect specific sequences of DNA or RNA that may or may not be associated with the disease such as single nucleotide polymorphism (SNP), deletions, rearrangements, and insertions, which are used for diagnosis and prediction of various infectious diseases, cancer, and other genetic disorders.

Asia-Pacific-Oncology-Molecular-Diagnostics-Market-2019-2026

Get more information on this report : Request Sample Pages

 

Factors such as increase in prevalence of various types of cancer, rise in awareness and acceptance of personalized medicines, and growth in biomarker identification drive the growth of this oncology molecular diagnostics market. Whereas, lack of skilled professional and stringent regulatory requirements for approval of new molecular diagnostic techniques restrain the Asia-Pacific oncology molecular diagnostics market growth.

The market is segmented on the basis of application, end user, and country. By application, it is segmented into colorectal, lung, hematological, breast, and others.. By end-user, it is categorized into hospitals, reference laboratories, and others (research institutes and academic institutes). 

Application segment review

On the basis of application, the oncology molecular diagnostics market is segmented into colorectal, lung, breast, hematological, and other cancers. 

Asia-Pacific Oncology Molecular Diagnostics Market
By Application

Your browser does not support the canvas element.

Lung cancer accounted for the largest segment

Get more information on this report : Request Sample Pages

 The others segment (includes prostate and gastric cancers) was the highest contributor with $111.16 million in 2018 and is estimated to reach $202.71 million by 2026, registering a CAGR of 8.3%, during the forecast period. This is attributed to increase in number of cancer cases and elevated mortality rates. Further, sub-standard prediction and limited access to timely diagnosis and treatment in many Asia-Pacific countries will restrict the growth of the Asia-Pacific oncology molecular diagnostics market. 

End user segment review

On the basis of end user, the global molecular diagnostics market is segmented into hospitals, reference laboratories, and others. The others segment includes academic institutions and research laboratories. The use of molecular diagnostics for cancer diagnosis by hospitals and reference laboratories assist physicians by providing an interpretation of genetic tests, such as explaining clinical importance of various tumors and pathogen genotypes, and identifying patients for treatment with new gene-based therapies for cancer. The hospitals segment was the highest contributor to the market, with $184.27 million in 2018, and is estimated to reach $354.46 million by 2026, at a CAGR of 9.0% during the forecast period.

Asia-Pacific Oncology Molecular Diagnostics Market
By End uer

Your browser does not support the canvas element.

Hospitals segment accounted for the largest share

Get more information on this report : Request Sample Pages

Country segment review

Country wise, the Asia-Pacific oncology molecular diagnostics market is analyzed across Australia, Vietnam, the Philippines, Thailand, and rest of Asia-Pacific. Australia was the highest contributor with $91.26 million in 2018, and is estimated to reach $175.55 million by 2026, registering a CAGR of 9.0% during the forecast period. This is attributed to rise in incidences of cancer cases and surge in demand for faster diagnosis of cancer. 

The report provides a comprehensive analysis of the key players operating in the Asia-Pacific Oncology Molecular Diagnostics market, namely F. Hoffmann-La Roche AG, BioMérieux SA, Abbott Laboratories, Qiagen N.V., Illumina, Danaher Corporation, S.A., Novartis AG, and Siemens Healthcare.

Key Benefits For Stakeholders

  • This report provides a detailed quantitative analysis of the current Asia-Pacific oncology molecular diagnostics market trends and forecast estimations from 2018 to 2026, which assists to identify the prevailing oncology molecular diagnostics market opportunities. 

  • An in-depth oncology molecular diagnostics market analysis includes analysis of various regions, which is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.

  • A comprehensive analysis of factors that drive and restrain the growth of the global is provided.

  • Country-wise market conditions are comprehensively analyzed in this report.

  • The projections in this report are made by analyzing the current trends and future market potential from 2019 to 2026, in terms of value.

  • An extensive analysis of various regions provides insights that are expected to allow companies to strategically plan their business moves.

  • Key market players within the oncology molecular diagnostics market are profiled in this report and their strategies are analyzed thoroughly, which helps in understanding competitive outlook of Asia-Pacific oncology molecular diagnostics market.

Key Market Segments

By Application

  • Breast cancer
    • By Technology 
      • PCR
    • By Type 
      • Instruments 
      • Reagents
      • Software & Services
  • NGS
    • By Type 
      • Instruments 
      • Reagents
      • Software & Services
  • Flow Cytometry 
    • By Type 
      • Instruments 
      • Reagents
      • Software & Services
  • FISH 
    • By Type
      • Instruments 
      • Reagents
      • Software & Services
  • CISH
    • By Type 
      • Instruments 
      • Reagents
      • Software & Services
  • Others
    • By Type 
      • Instruments 
      • Reagents
      • Software & Services
  • Lung cancer
    • By Technology 
      • PCR
        • By Type 
          • Instruments 
          • Reagents
          • Software & Services
  • NGS
    • By Type 
      • Instruments 
      • Reagents
      • Software & Services
  • Flow Cytometry 
    • By Type 
      • Instruments 
      • Reagents
      • Software & Services
  • FISH 
    • By Type
      • Instruments 
      • Reagents
      • Software & Services
  • CISH
    • By Type 
      • Instruments 
      • Reagents
      • Software & Services
  • Others
    • By Type 
      • Instruments 
      • Reagents
      • Software & Services
  • Colorectal  cancer
    • By Technology 
      • PCR
      • By Type 
      • Instruments 
      • Reagents
      • Software & Services
  • NGS
    • By Type 
      • Instruments 
      • Reagents
      • Software & Services
  • Flow Cytometry 
    • By Type 
      • Instruments 
      • Reagents
      • Software & Services
  • FISH 
    • By Type
      • Instruments 
      • Reagents
      • Software & Services
  • CISH
    • By Type 
      • Instruments 
      • Reagents
      • Software & Services
  • Others
    • By Type 
      • Instruments 
      • Reagents
      • Software & Services
  • Hematological cancer
    • By Technology 
      • PCR
        • By Type 
          • Instruments 
          • Reagents
          • Software & Services
  • NGS
    • By Type 
    • Instruments 
    • Reagents
    • Software & Services
  • Flow Cytometry 
    • By Type 
      • Instruments 
      • Reagents
      • Software & Services
  • FISH 
    • By Type
      • Instruments 
      • Reagents
      • Software & Services
  • CISH
    • By Type 
    • Instruments 
    • Reagents
    • Software & Services
  • Others
    • By Type 
      • Instruments 
      • Reagents
      • Software & Services
  • Other cancers
    • By Technology 
      • PCR
        • By Type 
          • Instruments 
          • Reagents
          • Software & Services
  • NGS
    • By Type 
      • Instruments 
      • Reagents
      • Software & Services
  • Flow Cytometry 
    • By Type 
      • Instruments 
      • Reagents
      • Software & Services
  • FISH 
    • By Type
      • Instruments 
      • Reagents
      • Software & Services
  • CISH
    • By Type 
      • Instruments 
      • Reagents
      • Software & Services
  • Others
    • By Type 
      • Instruments 
      • Reagents
      • Software & Services

By End user 

  • Hospitals
  • Reference Laboratories 
  • Others 

By Country

  • Australia
  • Thailand
  • The Philippines
  • Vietnam
  • Rest of Asia-Pacific
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits
1.3.Key market segments
1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Key findings

3.1.1.Top Investment Pockets
3.1.2.Top Player Positioning, 2018
3.1.3.Key forces shaping the Asia-Pacific oncology molecular diagnostics market

3.2.Market dynamics

3.2.1.Drivers

3.2.1.1.Rise in prevalence of various types of cancersW
3.2.1.2.Growth in funding by governmentsW
3.2.1.3.Growth in biomarker identification

3.2.2.Restraints

3.2.2.1.Lack of skilled professionals
3.2.2.2.Stringent regulatory requirements for product approvals

3.2.3.Opportunities

3.2.3.1.Advancements in genomics and proteomics

3.3.Regulatory guidelines for molecular diagnostics
3.4.Recommended guidelines for oncology molecular diagnostics tests
3.5.Insights on clinical flow cytometry panel
3.6.Pricing ranges for technology

CHAPTER 4:ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION

4.1.Overview

4.1.1.Asia-Pacific oncology molecular diagnostics market, by application

4.2.Colorectal cancer

4.2.1.Asia-Pacific oncology molecular diagnostics market, by technology for colorectal cancer
4.2.2.Colorectal oncology molecular diagnostics market, by PCR-based technology
4.2.3.Colorectal oncology molecular diagnostics market, by NGS based technology
4.2.4.Colorectal oncology molecular diagnostics market, by flow cytometry based technology
4.2.5.Colorectal oncology molecular diagnostics market, by FISH based technology
4.2.6.Colorectal oncology molecular diagnostics market, by CISH based technology
4.2.7.Colorectal oncology molecular diagnostics market, by others based technology

4.3.Hematological cancer

4.3.1.Market size and forecast
4.3.2.Hematological oncology molecular diagnostics market, by PCR-based technology
4.3.3.Hematological oncology molecular diagnostics market, by NGS based technology
4.3.4.Hematological oncology molecular diagnostics market, by flow cytometry based technology
4.3.5.Hematological oncology molecular diagnostics market, by FISH based technology
4.3.6.Hematological oncology molecular diagnostics market, by CISH based technology
4.3.7.Hematological oncology molecular diagnostics market, by others based technology

4.4.Breast cancer

4.4.1.Market size and forecast
4.4.2.Breast oncology molecular diagnostics market, by PCR-based technology
4.4.3.Breast oncology molecular diagnostics market, by NGS based technology
4.4.4.Breast oncology molecular diagnostics market, by flow cytometry based technology
4.4.5.Breast oncology molecular diagnostics market, by FISH based technology
4.4.6.Breast oncology molecular diagnostics market, by CISH based technology
4.4.7.Breast oncology molecular diagnostics market, by others based technology

4.5.Lung cancer

4.5.1.Market size and forecast
4.5.2.Lung oncology molecular diagnostics market, by PCR-based technology
4.5.3.Lung oncology molecular diagnostics market, by NGS based technology
4.5.4.Lung oncology molecular diagnostics market, by flow cytometry based technology
4.5.5.Lung oncology molecular diagnostics market, by FISH based technology
4.5.6.Lung oncology molecular diagnostics market, by CISH based technology
4.5.7.Lung oncology molecular diagnostics market, by others based technology

4.6.Other cancers

4.6.1.Market size and forecast
4.6.2.Others oncology molecular diagnostics market, by PCR-based technology
4.6.3.Others oncology molecular diagnostics market, by NGS based technology
4.6.4.Others oncology molecular diagnostics market, by flow cytometry based technology
4.6.5.Others oncology molecular diagnostics market, by FISH based technology
4.6.6.Others oncology molecular diagnostics market, by CISH based technology
4.6.7.Others oncology molecular diagnostics market, by others based technology

CHAPTER 5:ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER

5.1.Overview

5.1.1.Market size and forecast

5.2.Hospitals

5.2.1.Market size and forecast

5.3.Reference laboratories

5.3.1.Market size and forecast

5.4.Others

5.4.1.Market size and forecast

CHAPTER 6:ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY

6.1.Overview

6.1.1.Key market trends and opportunities
6.1.2.Asia-Pacific Oncology Molecular Diagnostics market, by country

6.2.Australia

6.2.1.Australia oncology molecular diagnostics market, by application
6.2.2.Australia oncology molecular diagnostics market, by end user
6.2.3.Market share analysis of top players, 2018

6.3.Vietnam

6.3.1.Vietnam oncology molecular diagnostics market, by application
6.3.2.Vietnam oncology molecular diagnostics market, by end user
6.3.3.Market share analysis of top players, 2018

6.4.Thailand

6.4.1.Thailand oncology molecular diagnostics market, by application
6.4.2.Thailand oncology molecular diagnostics market, by end user
6.4.3.Market share analysis of top players, 2018

6.5.Philippines

6.5.1.Philippines oncology molecular diagnostics market, by application
6.5.2.Philippines oncology molecular diagnostics market, by end user
6.5.3.Market share analysis of top players, 2018

6.6.Rest of Asia-Pacific

6.6.1.Rest of Asia-Pacific oncology molecular diagnostics market, by application
6.6.2.Rest of Asia-Pacific oncology molecular diagnostics market, by end user

CHAPTER 7:COMPANY PROFILES

7.1.ABBOTT LABORATORIES

7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance

7.2.bioMérieux SA

7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Product portfolio
7.2.4.Business performance
7.2.5.Key strategic moves and developments

7.3.Qiagen N.V. 

7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance
7.3.6.Key strategic moves and developments

7.4.F. Hoffmann-La Roche Ltd

7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance
7.4.6.Key strategic moves and developments

7.5.Siemens Healthineers

7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance

7.6.Danaher (Cepheid) 

7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.6.6.Key strategic moves and developments

7.7.Diasorin SPA

7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Product portfolio
7.7.4.Business performance
7.7.5.Key strategic moves and developments

7.8.Illumina Inc. 

7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.8.6.Key strategic moves and developments

7.9.Agilent Technologies Inc. 

7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance
7.9.6.Key strategic moves and developments

7.10.Sysmex Corporation

7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance
7.10.6.Key strategic moves and developments

LIST OF TABLES

TABLE 01.ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION) 
TABLE 02.ASIA PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY FOR COLORECTAL CANCER, 2018–2026 ($MILLION) 
TABLE 03.COLORECTAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY PCR-BASED TECHNOLOGY, 2018–2026 ($MILLION) 
TABLE 04.COLORECTAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY NGS BASED TECHNOLOGY, 2018–2026 ($MILLION) 
TABLE 05.COLORECTAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY FLOW CYTOMETRY BASED TECHNOLOGY,  2018–2026 ($MILLION) 
TABLE 06.COLORECTAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY FISH BASED TECHNOLOGY, 2018–2026 ($MILLION) 
TABLE 07.COLORECTAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY CISH BASED TECHNOLOGY, 2018–2026 ($MILLION) 
TABLE 08.COLORECTAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY OTHERS BASED TECHNOLOGY, 2018–2026 ($MILLION) 
TABLE 09.ASIA PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES , BY COUNTRY,  2018–2026 ($MILLION) 
TABLE 10.HEMATOLOGICAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY PCR-BASED TECHNOLOGY, 2018–2026 ($MILLION) 
TABLE 11.HEMATOLOGICAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY NGS BASED TECHNOLOGY, 2018–2026 ($MILLION) 
TABLE 12.HEMATOLOGICAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY FLOW CYTOMETRY BASED TECHNOLOGY,  2018–2026 ($MILLION) 
TABLE 13.HEMATOLOGICAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY FISH BASED TECHNOLOGY, 2018–2026 ($MILLION) 
TABLE 14.HEMATOLOGICAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY CISH BASED TECHNOLOGY, 2018–2026 ($MILLION) 
TABLE 15.HEMATOLOGICAL ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY OTHERS BASED TECHNOLOGY,  2018–2026 ($MILLION) 
TABLE 16.ASIA PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR BREAST CANCER , 2018–2026 ($MILLION) 
TABLE 17.BREAST ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY PCR-BASED TECHNOLOGY, 2018–2026 ($MILLION) 
TABLE 18.BREAST ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY NGS BASED TECHNOLOGY, 2018–2026 ($MILLION) 
TABLE 19.BREAST ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY FLOW CYTOMETRY BASED TECHNOLOGY,  2018–2026 ($MILLION) 
TABLE 20.BREAST ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY FISH BASED TECHNOLOGY, 2018–2026 ($MILLION) 
TABLE 21.BREAST ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY CISH BASED TECHNOLOGY, 2018–2026 ($MILLION) 
TABLE 22.BREAST ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY OTHERS BASED TECHNOLOGY, 2018–2026 ($MILLION) 
TABLE 23.ASIA PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR LUNG CANCER , 2018–2026 ($MILLION) 
TABLE 24.LUNG ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY PCR-BASED TECHNOLOGY, 2018–2026 ($MILLION) 
TABLE 25.LUNG ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY NGS BASED TECHNOLOGY, 2018–2026 ($MILLION) 
TABLE 26.LUNG ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY FLOW CYTOMETRY BASED TECHNOLOGY,  2018–2026 ($MILLION) 
TABLE 27.LUNG ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY FISH BASED TECHNOLOGY, 2018–2026 ($MILLION) 
TABLE 28.LUNG ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY CISH BASED TECHNOLOGY, 2018–2026 ($MILLION) 
TABLE 29.LUNG ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY OTHERS BASED TECHNOLOGY, 2018–2026 ($MILLION) 
TABLE 30.ASIA PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR OTHERS , BY COUNTRY , 2018–2026 ($MILLION) 
TABLE 31.OTHERS ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY PCR-BASED TECHNOLOGY, 2018–2026 ($MILLION) 
TABLE 32.OTHERS ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY NGS BASED TECHNOLOGY, 2018–2026 ($MILLION) 
TABLE 33.OTHERS ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY FLOW CYTOMETRY BASED TECHNOLOGY, 2018–2026 ($MILLION) 
TABLE 34.OTHERS ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY FISH BASED TECHNOLOGY, 2018–2026 ($MILLION) 
TABLE 35.OTHERS ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY CISH BASED TECHNOLOGY, 2018–2026 ($MILLION) 
TABLE 36.OTHERS ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY OTHERS BASED TECHNOLOGY, 2018–2026 ($MILLION) 
TABLE 37.ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER 2018–2026 ($MILLION) 
TABLE 38.ASIA PACIFIC ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY ,  2018–2026 ($MILLION) 
TABLE 39.ASIA PACIFIC ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES , BY COUNTRY , 2018–2026 ($MILLION) 
TABLE 40.ASIA PACIFIC ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET FOR OTHERS , BY COUNTRY ,  2018–2026 ($MILLION) 
TABLE 41.ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2018–2026 ($MILLION) 
TABLE 42.AUSTRALIA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION) 
TABLE 43.AUSTRALIA ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2026 ($MILLION) 
TABLE 44.VIETNAM ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION) 
TABLE 45.VIETNAM ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2026 ($MILLION) 
TABLE 46.THAILAND ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION) 
TABLE 47.THAILAND ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2026 ($MILLION) 
TABLE 48.PHILLIPINES ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION) 
TABLE 49.PHILLIPINES ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2026 ($MILLION) 
TABLE 50.REST OF ASIA PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION) 
TABLE 51.REST OF ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2018–2026 ($MILLION) 
TABLE 52.ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 53.ABBOTT LABORATORIES: OPERATING SEGMENTS
TABLE 54.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 55.BIOMEREUX SA: COMPANY SNAPSHOT
TABLE 56.BIOMEREUX SA: PRODUCT PORTFOLIO
TABLE 57.BIOMEREUX SA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 58.QIAGEN N.V.: COMPANY SNAPSHOT
TABLE 59.QIAGEN N.V.: OPERATING SEGMENT
TABLE 60.QIAGEN N.V.: PRODUCT PORTFOLIO
TABLE 61.QIAGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 62.F. HOFFMAN-LA ROCHE LTD: COMPANY SNAPSHOT
TABLE 63.F. HOFFMAN-LA ROCHE LTD: OPERATING SEGMENTS
TABLE 64.F. HOFFMAN-LA ROCHE LTD: PRODUCT PORTFOLIO
TABLE 65.F. HOFFMAN-LA ROCHE LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 66.SIEMENS HEALTHINEERS: COMPANY SNAPSHOT
TABLE 67.SIEMENS HEALTHINEERS: OPERATING SEGMENTS
TABLE 68.SIEMENS HEALTHINEERS: PRODUCT PORTFOLIO
TABLE 69.DANAHER CORPORATION: COMPANY SNAPSHOT
TABLE 70.DANAHER CORPORATION: OPERATING SEGMENTS
TABLE 71.DANAHER CORPORATION: PRODUCT PORTFOLIO
TABLE 72.DANAHER CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 73.DIASORIN SPA: COMPANY SNAPSHOT
TABLE 74.DIASORIN SPA: PRODUCT PORTFOLIO
TABLE 75.DIASORIN SPA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 76.ILLUMINA INC.: COMPANY SNAPSHOT
TABLE 77.ILLUMINA INC.: OPERATING SEGMENTS
TABLE 78.ILLUMINA INC.: PRODUCT PORTFOLIO
TABLE 79.ILLUMINA INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 80.AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT
TABLE 81.AGILENT TECHNOLOGIES INC.: OPERATING SEGMENTS
TABLE 82.AGILENT TECHNOLOGIES INC: PRODUCT PORTFOLIO
TABLE 83.AGILENT TECHNOLOGIES INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 84.SYSMEX CORPORATION: COMPANY SNAPSHOT
TABLE 85.SYSMEX CORPORATION: OPERATING SEGMENTS
TABLE 86.SYSMEX CORPORATION: PRODUCT PORTFOLIO
TABLE 87.SYSMEX CORPORATION.: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 01.TOP INVESTMENT POCKETS
FIGURE 02.TOP PLAYER POSITIONING, 2018
FIGURE 03.LOW BARGAINAING POWER OF BUYERS
FIGURE 04.MODERATE BARGAINAING POWER OF SUPPLIERS
FIGURE 05.LOW THREAT OF SUBSITUTION
FIGURE 06.MODERATE THREAT OF NEW ENTRANTS
FIGURE 07.HIGHLY COMPETITIVE RIVALRY
FIGURE 08.MARKET DYNAMICS
FIGURE 09.MARKET SHARE ANALYSIS OF TOP PLAYERS, 2018
FIGURE 10.MARKET SHARE ANALYSIS OF TOP PLAYERS, 2018
FIGURE 11.MARKET SHARE ANALYSIS OF TOP PLAYERS, 2018
FIGURE 12.MARKET SHARE ANALYSIS OF TOP PLAYERS, 2018
FIGURE 13.MARKET SHARE ANALYSIS OF TOP PLAYERS, 2018
FIGURE 14.ABBOTT LABORATORIES: NET SALES, 2016–2018 ($MILLION) 
FIGURE 15.ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2018 (%)
FIGURE 16.ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2018 (%)
FIGURE 17.BIOMEREUX SA.: NET SALES, 2016–2018 ($MILLION) 
FIGURE 18.BIOMEREUX SA: REVENUE SHARE, BY REGION, 2018 (%)
FIGURE 19.QIAGEN N.V.: NET SALES, 2016–2018 ($MILLION) 
FIGURE 20.QIAGEN N.V.: REVENUE SHARE, BY PRODUCT CATEGORY, 2018 (%)
FIGURE 21.QIAGEN N.V.: REVENUE SHARE, BY REGION, 2018 (%)
FIGURE 22.F. HOFFMAN-LA ROCHE LTD: NET SALES, 2017–2019 ($MILLION) 
FIGURE 23.F. HOFFMAN-LA ROCHE LTD: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 24.SIEMENS HEALTHINEERS: NET SALES, 2017–2019 ($MILLION)131
FIGURE 25.SIEMENS HEALTHINEERS: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 26.SIEMENS HEALTHINEERS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 27.DANAHER CORPORATION: NET SALES, 2016–2018 ($MILLION)135
FIGURE 28.DANAHER CORPORATION: REVENUE SHARE, BY SEGMENT, 2018 (%)
FIGURE 29.DANAHER CORPORATION: REVENUE SHARE, BY REGION, 2018 (%)
FIGURE 30.DIASORIN SPA: NET SALES, 2016–2018 ($MILLION) 
FIGURE 31.DIASORIN SPA: REVENUE SHARE, BY REGION, 2018 (%)
FIGURE 32.ILLUMINA INC: NET SALES, 2017–2019 ($MILLION) 
FIGURE 33.ILLUMINA INC: REVENUE SHARE, BY PRODUCTS, 2019 (%)
FIGURE 34.ILLUMINA INC: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 35.AGILENT TECHNOLOGIES INC: NET SALES, 2017–2019 ($MILLION) 
FIGURE 36.AGILENT TECHNOLOGIES INC: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 37.AGILENT TECHNOLOGIES INC: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 38.SYSMEX CORPORATION: NET SALES, 2017–2019 ($MILLION)
FIGURE 39.SYSMEX CORPORATION: REVENUE SHARE, BY REGION, 2019 (%)

 
 

Molecular diagnostics is a set of cumulative techniques used for analyzing biological markers at molecular level such as genome and proteome. It is used for diagnosis and prediction of various cancers, and other genetic disorders. 

Advancements in molecular diagnostics, including increased precision, faster turnarounds, and reduced costs act as key drivers for better genetic information. Furthermore, leading companies in the market, personalized medicine approach, cost-effective treatment, and technological advancements are some of the major factors that drive the market growth. However, stringent regulatory policies are anticipated to hamper the overall growth of the market. Presently, hospitals are the largest end users of molecular diagnostic techniques followed by reference laboratories. 

Many medical diagnostic product manufacturing companies are investing in R&D for development of advanced molecular diagnostics tests. Moreover, rise in well-equipped hospitals and clinics for the treatment of cancer patients and surge in awareness among people about personalized medicines in the region is responsible for the growth of the Asia-Pacific oncology molecular diagnostics market. 

 

PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library,  T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

FREQUENTLY ASKED QUESTIONS?
 

A. The total value of Asia-Pacific Oncology Molecular Diagnostics market was $381.4 million in 2018.

A. The forecast period in the report is from 2019-2026.

A. The market value of Asia-Pacific Oncology Molecular Diagnostics market in 2019 was $400.93 million.

A. The base year calculated is 2018 in the report.

A. Surge in technological advancements in the oncology molecular diagnostics.

A. The growth % of the Asia-Pacific Oncology Molecular Diagnostics market is 9%.

A. Application segment holds the maximum market share.

A. Rest of Asia-Pacific market holds the maximum market share.

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Asia-Pacific Oncology Molecular Diagnostics Market

  • Online Only
  • $3,121
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,468
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,249
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $5,825
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,124
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This title and over 12,000+ are available on the Avenue Library.  T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts